Dynatronics - DYNT Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynatronics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DYNT shares.
View DYNT analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued twelve-month price targets for Dynatronics' shares. Their DYNT share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 832.6% from the stock's current price.
View analysts price targets for DYNT or view top-rated stocks among Wall Street analysts.

Dynatronics' stock was trading at $1.00 at the start of the year. Since then, DYNT shares have decreased by 57.1% and is now trading at $0.4289.
View the best growth stocks for 2022 here.

Dynatronics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 144,200 shares, an increase of 20.5% from the October 31st total of 119,700 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is presently 5.1 days. Currently, 1.1% of the shares of the company are sold short.
View Dynatronics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our DYNT earnings forecast.

Dynatronics Co. (NASDAQ:DYNT) released its quarterly earnings data on Thursday, September, 22nd. The medical equipment provider reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The medical equipment provider had revenue of $11.19 million for the quarter, compared to analysts' expectations of $11.22 million. Dynatronics had a negative net margin of 11.30% and a negative trailing twelve-month return on equity of 33.81%.

Dynatronics issued an update on its FY 2023 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.00 million-$48.00 million, compared to the consensus revenue estimate of $46.34 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynatronics investors own include Biocept (BIOC), Nuwellis (CHFS), Heat Biologics (HTBX), Bionano Genomics (BNGO), iBio (IBIO), Alto Ingredients (PEIX), Sorrento Therapeutics (SRNE), Ampio Pharmaceuticals (AMPE), Palatin Technologies (PTN) and Electrameccanica Vehicles (SOLO).

Dynatronics trades on the NASDAQ under the ticker symbol "DYNT."

Dynatronics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.52%) and Perritt Capital Management Inc. (0.75%).
View institutional ownership trends.

Shares of DYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DYNT stock can currently be purchased for approximately $0.43.

Dynatronics (NASDAQ:DYNT) has a market capitalization of $8.14 million and generates $44.34 million in revenue each year. The medical equipment provider earns $-3,990,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

The company employs 170 workers across the globe.

Dynatronics' mailing address is 1200 TRAPP ROAD, EAGAN MN, 55121. The official website for the company is www.dynatronics.com. The medical equipment provider can be reached via phone at (801) 568-7000, via email at jim.ogilvie@dynatronics.com, or via fax at 801-568-7711.